• Corpus ID: 55372752

Role of Traditional Risk Factors, Inflammation and DMARDs in Cardiovascular Diseases in Rheumatoid Arthritis and Management of Lipid Profile

  title={Role of Traditional Risk Factors, Inflammation and DMARDs in Cardiovascular Diseases in Rheumatoid Arthritis and Management of Lipid Profile},
  author={Mariam S Aziz and Khushwant S. Yadav},
We will review the interaction of traditional risk factors (dyslipidemia, obesity, insulin resistance, diabetes, hypertension, cigarette smoking and physical inactivity), inflammation, DMARDs in cardiovascular diseases in Rheumatoid Arthritis (RA) patients. 

Figures and Tables from this paper

The Effect of Vitamin Supplementation on Subclinical Atherosclerosis in Patients without Manifest Cardiovascular Diseases: Never-ending Hope or Underestimated Effect?
There are no conclusive data on the prevention and progression of atherosclerosis based on vitamin supplementation, however, given their enormous potential, future trials are certainly needed for a more tailored CVD prevention focusing on early stages as subclinical Atherosclerosis.
This dissertation aims to provide a history of pri-Med Care in Bhopal, India and its use in the context of modern medicine and its role in the treatment of cancer.


Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease
Inflammatory measures (particularly, ESR) are significantly associated with the risk of CVD in RA, whereby lower TCh and LDL levels are associated with increased cardiovascular risk.
Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation.
The role of pro-inflammatory cytokines and their inhibitors in RA are focused on, and whether they may be causal in the accelerated atherosclerosis seen in these patients.
Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms.
The pathogenesis of insulin resistance and its contribution to atherogenesis varies in different inflammatory settings.
Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.
The data suggest increases in lipid levels between baseline and end of study in clinical trials of RA patients treated with biologic DMARDs, but the clinical implications of this finding with regard to cardiovascular outcomes are not clear.
Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis.
An understanding of how systemic inflammation in RA accelerates atherosclerosis is provided, which should guide therapeutic targets to minimize CV risk in RA, and may lead to insights into the inflammatory mechanisms of Atherosclerosis in general.
Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment.
Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis.
Both established CV risk factors and manifestations of RA inflammation contribute significantly to carotid atherosclerosis in RA, and may modify one another's effects, which may have implications regarding the prevention of atheros sclerosis in RA.
Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
Changes in lipid profiles, particularly increases in cholesterol and triglycerides that occur with treatments for severe inflammation, may not represent increased cardiovascular risk as in the usual understanding of lipid-level elevations in individuals without significant inflammation, but may represent a predictable response to attenuation of inflammation.
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
Patients using a TNF antagonist experienced a reduced risk of the primary composite cardiovascular endpoint and the risk reduction associated with TNF antagonists was also observed for non-fatal cardiovascular events.
A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis
A systematic review of the literature found a small trend to increased TC was observed in patients receiving TNF-α antagonists, mostly due to an increase in HDL, but the clinical impact of these findings is unclear, and further studies are needed to clarify the role of these lipid changes on cardiovascular morbidity in RA.